siRNAs for Lilly Direct? Not what I would have expected. But that’s where
@EliLillyandCo CEO Dave Ricks is looking given how cleanly targeted the modality is, and how infrequent the dosing can be.
His view: therapies that prevent disease, with almost no symptoms to manage, fit a direct channel.
“That seems like a pretty viable idea to us.”’